A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer.
about
A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumabDual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancerUnraveling breast cancer heterogeneity through transcriptomic and epigenomic analysis.Phase I dose-escalation study of 5-day intermittent oral lapatinib therapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer.Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas.Management of ErbB2-positive breast cancer: insights from preclinical and clinical studies with lapatinib.Therapeutic Considerations in Treating HER2-Positive Metastatic Breast CancerPresent and future evolution of advanced breast cancer therapy.The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics.Targeted treatment of advanced and metastaticbreast cancer with lapatinib.Role of lapatinib in the first-line treatment of patients with metastatic breast cancer.Resiliency and vulnerability in the HER2-HER3 tumorigenic driver.Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausalHER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies.Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline-based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 study.Targeting the HER/EGFR/ErbB family to prevent breast cancer.Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck.Integrating molecular mechanisms and clinical evidence in the management of trastuzumab resistant or refractory HER-2⁺ metastatic breast cancer.Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer.Targeted Therapies in Breast Cancer: Implications for Advanced Oncology Practice.Efficacy and tolerability of lapatinib in the management of breast cancerObatoclax and lapatinib interact to induce toxic autophagy through NOXA.Systematic Review of the Side Effects Associated With Anti-HER2-Targeted Therapies Used in the Treatment of Breast Cancer, on Behalf of the EORTC Quality of Life Group.Phase I study of lapatinib plus vinorelbine in patients with locally advanced or metastatic breast cancer overexpressing HER2.Two dimensions in targeting HER2.Mechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast CancerTargeting angiogenesis in metastatic breast cancerEfficacy and mechanism of action of the tyrosine kinase inhibitors gefitinib, lapatinib and neratinib in the treatment of HER2-positive breast cancer: preclinical and clinical evidencePhase I and pharmacological trial of lapatinib in combination with gemcitabine in patients with advanced breast cancerA TORC2-Akt Feed-Forward Topology Underlies HER3 Resiliency in HER2-Amplified Cancers.Is the Improved Efficacy of Trastuzumab and Lapatinib Combination Worth the Added Toxicity? A Discussion of Current Evidence, Recommendations, and Ethical Issues Regarding Dual HER2-Targeted Therapy.Chemical probing of HER2-amplified cancer cells identifies TORC2 as a particularly effective secondary target for combination with lapatinibPsoriasis aggravation due to lapatinibCombination neratinib (HKI-272) and paclitaxel therapy in patients with HER2-positive metastatic breast cancer.Phase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2+ Breast CancerHER2 breast cancer therapies: a reviewSignal integration: a framework for understanding the efficacy of therapeutics targeting the human EGFR familyRole of epidermal growth factor receptor in breast cancer.Jumping higher: is it still possible? The ALTTO trial challenge.Lapatinib: new opportunities for management of breast cancer.
P2860
Q24594725-F246AEFB-FC9B-4EBD-B54A-2E35D2AFCEFAQ26785612-AB338FD2-C8BE-4101-9C56-E7021259C68CQ33570282-9D4D543A-3B17-4B84-B4C3-CEBA7C7A7270Q33597447-031C1E47-B9F8-46C5-9E2F-F9021F3F674BQ33750719-ED7C693E-8131-4AEF-9D17-314F9E315CDDQ34241118-E11ABF1A-C6A9-4A40-A9CE-4645D1034969Q34268618-6294FA40-4C4E-467E-BA5F-031663A7074EQ34274925-AF60DBE7-C6C3-44D7-B275-02C2F4B30D32Q34349389-1A7D87F0-B42B-4632-80B5-A972D6DAC135Q34363419-B350E3CF-A71C-446A-8538-98743CFC969DQ34417920-71AFD451-492D-4756-BE1E-E6CE7B048D9CQ34551761-5C3056D4-45CE-408D-8A80-5D949522C2A0Q34611634-83DCEE99-5B5A-4405-94D6-0AC5DE24649FQ34974436-7815125D-6FFB-4560-9019-8B09B76AD3DAQ35005762-4BC2A0E7-7782-4D9A-A301-652A4F650FB7Q35208654-65CBE39A-9ED4-4471-AC63-6A25877DCFF2Q35287729-035CF961-79E3-4C2A-A301-82657682D9CCQ35599781-DC2781AD-9C37-4D3D-AF08-76A7D907C6E6Q35653820-633AF4AE-32CD-4C42-8A71-9C7D241191D6Q35687574-B7FFC31E-C2C3-4AB8-A4B2-49C69AE13622Q35835926-5FC3DFAD-97ED-490E-B002-169F76346F38Q35846880-99CA19E1-DAA8-4DEA-83C5-AA29923FE9BFQ35871467-59460F50-20CE-4837-810E-8CE9231641A8Q35879839-F77D72E3-B23A-43E3-AAFB-840EBF6F3FBFQ35895143-78CA0D9E-E400-46B0-ABFA-0A937853261EQ35977527-EB1EB7EE-4D61-4C9C-BFE6-6344C0433F2BQ36182795-602E8A2D-62EC-474F-9D3E-7F7425FAAFB5Q36250585-EBC00E7F-A588-44AC-9399-FC3AFB9295E9Q36289916-E99B1285-99BB-47B1-9154-DFD03780380DQ36359705-C550D5FD-1DAA-4EE8-8B3A-669A06DDF04AQ36440625-A908F2F5-B93E-4852-B4A3-7AD6D5FC6547Q36562299-256E9169-EA15-47C7-AC61-200E4F3DC770Q36704672-7B6C1D6E-E52C-49FE-B677-EFD921E12224Q36896150-535C9235-D63D-4FD3-B307-B04FC0A241EAQ36963374-06C6FAB1-441B-411A-87C6-83493C02D1BCQ37303196-AEB2DEE7-118A-448F-8562-0592E0925374Q37316604-74D59F06-9C0E-483B-9B8F-FF96E04ACF33Q37320346-05B9241F-2A28-4E75-B081-892C425C1E23Q37338235-25997BA8-A99D-4BAE-AFA2-E22133FEE2BBQ37355729-BFF6D51F-5F0D-4472-BFE1-6B9688540C73
P2860
A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 17 February 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A phase II study of lapatinib ...... d or metastatic breast cancer.
@en
A phase II study of lapatinib ...... d or metastatic breast cancer.
@nl
type
label
A phase II study of lapatinib ...... d or metastatic breast cancer.
@en
A phase II study of lapatinib ...... d or metastatic breast cancer.
@nl
prefLabel
A phase II study of lapatinib ...... d or metastatic breast cancer.
@en
A phase II study of lapatinib ...... d or metastatic breast cancer.
@nl
P2093
P356
P1433
P1476
A phase II study of lapatinib ...... d or metastatic breast cancer.
@en
P2093
A M Storniolo
H J Burstein
K L Blackwell
V M Salazar
P304
P356
10.1093/ANNONC/MDM601
P577
2008-02-17T00:00:00Z